In today’s recent session, 0.58 million shares of the Legend Biotech Corp ADR (NASDAQ:LEGN) have been traded, and its beta is 0.08. Most recently the company’s share price was $40.15, and it changed around $1.75 or 4.56% from the last close, which brings the market valuation of the company to $7.37B. LEGN at last check was trading at a discount to its 52-week high of $70.13, offering almost -74.67% off that amount. The share price’s 52-week low was $36.92, which indicates that the recent value has risen by an impressive 8.04% since then. We note from Legend Biotech Corp ADR’s average daily trading volume that its 10-day average is 2.03 million shares, with the 3-month average coming to 1.20 million.
Legend Biotech Corp ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.24. If we narrow it down even further, the data shows that 0 out of 27 analysts rate the stock as a Sell; another 10 rate it as Overweight. Among the rest, 2 recommended LEGN as a Hold, whereas 15 deemed it a Buy, and 0 rated it as Underweight. Legend Biotech Corp ADR is expected to report earnings per share of -0.31 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN has been showing a green trend so far today with a performance of 4.56% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 41.00 on recent trading dayincreased the stock’s daily price by 2.07%. The company’s shares are currently down -33.27% year-to-date, but still up 2.04% over the last five days. On the other hand, Legend Biotech Corp ADR (NASDAQ:LEGN) is -10.84% down in the 30-day period. We can see from the shorts that 15.86 million shares have been sold at a short interest cover period of 12.18 day(s).
The consensus price target as assigned by Wall Street analysts is $86, which translates to bulls needing to increase their stock price by 53.31% from its current value. Analyst projections state that LEGN is forecast to be at a low of $60 and a high of $94.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Legend Biotech Corp ADR share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -5.75 percent over the past six months and at a 16.33% annual growth rate that is well below the industry average of 18.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 61.65% in revenue this quarter, and will report an increase of 19.79% in the next quarter. The year-over-year growth rate is expected to be 120.10%, up from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 180.32M in revenue for the current quarter. 5 analysts expect Legend Biotech Corp ADR to make 196.48M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 79.46M and 93.99M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 126.92%. Forecasts for the next quarter put sales growth at 109.04%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -168.48%.
LEGN Dividends
Legend Biotech Corp ADR’s next quarterly earnings report is expected to be released in December.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
PRICE T ROWE ASSOCIATES INC /MD/, with 6.3126% or 11.49 million shares worth $508.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Health Care and Price (T.Rowe) Growth Stock Fund Inc. were the top two Mutual Funds as of Sep 30, 2024. The former held 2.6 shares worth $103.62 million, making up 1.43% of all outstanding shares. On the other hand, Price (T.Rowe) Growth Stock Fund Inc. held roughly 2.4 shares worth around $95.62 million, which represents about 1.32% of the total shares outstanding.
